CAMBRIDGE, Mass., Nov. 13, 2014 /PRNewswire/ -- Blueprint Medicines, a leader in discovering and developing highly selective kinase inhibitors for genomically defined cancers, today announced that a research study identifying several new cancer drug targets known as fusion genes will be presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, on November 20, 2014. The presentation by Blueprint Medicines’ Chief Scientific Officer Christoph Lengauer, PhD, MBA, will highlight the implications of these discoveries for drug development as well as their immediate impact on diagnosis and treatment of cancer patients.
“These findings exemplify the significant potential of Blueprint Medicines’ kinase discovery platform to uncover novel genetic drivers of disease,” said Dr. Lengauer. “Our sole focus on kinases has led us to develop unique tools and techniques that allow for improved detection of kinase fusions, which make excellent targets for drug discovery. Blueprint is leveraging these findings in building its proprietary pipeline of highly selective inhibitors against genomically defined cancers.”
In his presentation, Dr. Lengauer will review the research approach and outcomes, parts of which were previously published in Nature Communications (Stransky N. et al., The landscape of kinase fusions in cancer).
Details of the oral presentation are as follows:
- Presentation: “The Landscape of Kinase Fusions in Cancer”
- Plenary Session 7: Novel Mechanisms for Drug Resistance
- Date & Time: Thursday, November 20, 2014, 5:00 p.m. 5:20 p.m. CET (12:00 p.m. 12:20 p.m. EDT)
- Location: Auditorium, Centre de Convencions Internacional Barcelona
About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancer patients. Led by a management team and advisors with world renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint Medicines has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint Medicines to rapidly discover potent and highly selective drugs against clear drivers of diseases. Founded in 2011, Blueprint Medicines is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit www.BlueprintMedicines.com.
Contacts:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212 362 1200
beth@sternir.com
Media Relations:
David Polk
Chandler Chicco Companies
310 309 1029
dpolk@chandlerchiccocompanies.com
SOURCE Blueprint Medicines
Help employers find you! Check out all the jobs and post your resume.
